Close Menu

NEW YORK (GenomeWeb) – GenomeDx Biosciences announced today that Medicare administrative contractor Noridian GBA has issued a draft local coverage determination for use of the firm's Decipher Prostate Biopsy genomic classifier in patients with very low and low-risk prostate cancer as defined by National Comprehensive Cancer Network guidelines.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.